The FDA has granted breakthrough device designation to the novel, microbiome-driven, liquid biopsy assay OncobiotaLUNG for the detection of lung carcinomas, according to a press release from developer Micronoma.1

The assay is one of the first blood microbiome­–driven assays to demonstrate confirmed efficacy such as identification of early-stage lung cancer, according to Micronoma. The assay could potentially improve standard-of-care strategies for those with lung nodules who may have lung carcinoma, detecting disease as early as stage I

Read more at The Cancer Network